They, furthermore, imply specific changes in strategies for cancer patient care: our model suggests that inhibition of RAD52/POLθ pathways as adjuvant therapy concomitant with initial conventional therapy could offer an actionable strategy for ameliorating aggressive tumor evolution and secondary mutations leading to resistance in p53-defective tumors. Here, TP53 is linked to cancer.